Abstract
Using a real-time RT-PCR method, we analyzed the expression of e1a2 BCR-ABL mRNA in bone marrow samples from 13 patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia (ALL) at different time points during chemotherapy and after bone marrow transplantation (BMT). The detection limit of the method, assessed using serial dilutions of ALL/MIK cells, was found to be 1:105, similar to what is observed for the conventional RT-nested PCR method. The e1a2 BCR-ABL values were normalized with respect to those of the housekeeping gene GAPDH. The decrease in the e1a2 BCR-ABL/GAPDH ratio after remission induction chemotherapy reflects well the response to chemotherapy and consequently correlates with the prognosis. Although molecular remission was achieved by chemotherapy alone, some patients relapsed, and the e1a2 BCR-ABL/GAPDH ratios in these cases progressively increased to the levels seen prior to hematological relapse. Long-term hematological complete remission (more than 30 months) could be achieved in cases in which a more than 4.0 log decrease in the e1a2 BCR-ABL/GAPDH ratio was obtained by chemotherapy alone, and BMT was then performed. In conclusion, real-time RT-PCR allows for an evaluation of the kinetics of e1a2 BCR-ABL/GAPDH expression during the various phases of chemotherapy or after BMT and may be effective for the indication and control of disease relapse in Ph-positive ALL patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hermans A, Heisterkamp N, von Lindern M, van Baal S, Meijer D, van der Plas D, Wiedemann LM, Groffen J, Bootsma D, Grosveld G . Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia Cell 1987 51: 33–40
Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON . Expression of a distinctive BCR-ABL oncogene in Ph-positive acute lymphocytic leukemia (ALL) Science 1988 239: 775–777
Schaefer-Rego K, Arlin Z, Shapiro LG, Mears JG, Leibowitz D . Molecular heterogeneity of adult Philadelphia chromosome-positive acute lymphoblastic leukemia Cancer Res 1988 48: 866–869
Bloomfield CD, Goldman AI, Alimena G, Berger R, Borgstrom GH, Brandt L, Catovsky D, de la Chapelle A, Dewald GW, Garson OM, Garwicz S, Golomb HM, Hossfeld DK, Lawler SD, Mitelman F, Nilsson P, Pierre RV, Philip P, Prigogina E, Rowely JD, Sakurai M, Sandberg AA, Secker-Walker LM, Tricot G, Van Den Berghe H, Van Orshoven A, Vuopio P, Whang-Peng J . Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia Blood 1986 67: 415–420
Fenaux P, Lai JL, Morel P, Nelken B, Taboureau O, Deminatti M, Bauters F . Cytogenetics and their prognostic value in childhood and adult acute lymphoblastic leukemia (ALL) excluding L3 Hematol Oncol 1989 7: 307–317
Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV . Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance Leukemia 1991 5: 196–199
Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, Wurster-Hill DH, Sobol RE, Schiffer C, Bloomfield CD . Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762) Blood 1992 80: 2983–2990
Maurer J, Janssen JW, Thiel E, van Denderen J, Ludwig WD, Aydemir U, Heinze B, Fonatsch C, Harbott J, Reiter A, Riehm H, Hoelzer D, Bartram CR . Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction Lancet 1991 337: 1055–1058
Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpaz M, Trujillo JM, Blick M, Beran M, Gutterman JU . A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia Nature 1987 325: 631–635
Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, Dreazen O, Smith SD, Croce CM . A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia Nature 1987 330: 386–388
Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP . Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro Proc Natl Acad Sci USA 1988 85: 5698–5702
Kurzrock R, Gutterman JU, Talpaz M . The molecular genetics of Philadelphia chromosomepositive leukemias N Engl J Med 1988 319: 990–998
Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R . Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia Blood 1991 78: 2411–2418
Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R, Kirk J, Lee A, Kessler P, Appelbaum F, Gehly G . Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction Leukemia 1994 8: 1688–1695
Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JW, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig WD, Riehm H, Lampert F, Harbott J . Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05–92 Leukemia 1996 10: 957–963
Hoelzer D, Thiel E, Loeffler H, Bodenstein H, Plaumann L, Buechner T, Urbanitz D, Koch P, Heimpel H, Engelhardt R, Mueller U, Wendt FC, Sodomann H, Ruehl H, Herrmann F, Kaboth W, Dietzfelbinger H, Pralle H, Lunscken C, Hellriegel KP, Spors S, Nowrousian RM, Fischer J, Fuelle H, Mitrou PS, Pfreundschuh M, Goerg C, Emmerich B, Queisser W, Meyer P, Labedzki L, Essers U, Koenig H, Mainzer K, Herrmann R, Messerer D, Zwingers T . Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults Blood 1984 64: 38–47
Hoelzer D . Treatment of acute lymphoblastic leukemia Semin Hematol 1994 31: 1–15
Miyamura K, Tanimoto M, Morishima Y, Horibe K, Yamamoto K, Akatsuka M, Kodera Y, Kojima S, Matsuyama K, Hirabayashi N, Yazaki M, Imai K, Onozawa Y, Kanamaru A, Mizutani S, Saito H . Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation Blood 1992 79: 1366–1370
Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldman JM, Henslee-Downey PJ, Herzig RH, Speck B, Zwaan FE, Bortin MM . Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 1992 79: 3067–3070
Chao NJ, Blume KG, Forman SJ, Snyder DS . Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 1995 85: 3353–3354
Gehly GB, Bryant EM, Lee AM, Kidd PG, Thomas ED . Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 1991 78: 458–465
Mitterbauer G, Fodinger M, Scherrer R, Knobl P, Jager U, Laczika K, Schwarzinger I, Gaiger A, Geissler K, Greinix H, Kalhs P, Linkesch W, Lechner K . Mannhalter C. PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia Br J Haematol 1995 89: 937–941
Preudhomme C, Henic N, Cazin B, Lai JL, Bertheas MF, Vanrumbeke M, Lemoine F, Jouet JP, Deconninck E, Nelken B, Cosson A, Fenaux P . Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL) Leukemia 1997 11: 294–298
Sierra J, Radich J, Hansen JA, Martin PJ ., Petersdorf EW, Bjerke J, Bryant E, Nash RA, Sanders JE, Storb R, Sullivan KM, Appelbaum FR, Anasetti C. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 1997 90: 1410–1414
Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, Gooley T, Kessler P, Kirk J, Ladne P, Thomas ED, Appelbaum FR . Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after bone marrow transplantation Blood 1997 89: 2602–2609
van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NC, Goldman JM . Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow Leukemia 1995 9: 329–335
Mitterbauer G, Nemeth P, Wacha S, Cross NC, Schwarzinger I, Jaeger U, Geissler K, Greinix HT, Kalhs P, Lechner K, Mannhalter C . Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction Br J Haematol 1999 106: 634–643
Higa T, Okabe M, Kunieda Y, Kodama S, Itaya T, Kurosawa M, Sakurada K, Maekawa I, Shoji M, Kasai M, Miyazaki T . Establishment and characterization of a new Ph1-positive ALL cell line (ALL/MIK) presenting bcr gene rearrangement on bcr-2 and ALL-type bcr/abl transcript: suggestion of in vitro differentiation to monocytoid lineage Leuk Lymphoma 1994 12: 287–96
Koeffler HP, Golde DW . Human myeloid leukemia cell lines: a review Blood 1980 56: 344–350
Martin H, Atta J, Bruecher J, Elsner S, Schardt C, Stadler M, von Melchner H, Hoelzer D . In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT Ann Hematol 1994 68: 85–87
Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW . The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage Ann Hematol 2000 79: 424–431
Barbany G, Hagberg A, Olsson-Stromberg U, Simonsson B, Syvanen AC, Landegren U . Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients Clin Chem 2000 46: 913–920
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 1996 2: 561–566
Kawaguchi Y, Jinnai I, Nagai K, Yagasaki F, Yakata Y, Matsuo T, Kuriyama K, Tomonaga M . Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells Leukemia 2001 15: 590–594
Acknowledgements
We thank Mrs Emiko Takahashi, Mr Ryoichi Saito and Mr Junichi Hayakawa for their excellent technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yokota, H., Tsuno, N., Tanaka, Y. et al. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia 16, 1167–1175 (2002). https://doi.org/10.1038/sj.leu.2402483
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402483
Keywords
This article is cited by
-
Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation
International Journal of Hematology (2022)
-
Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia
International Journal of Hematology (2021)
-
Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT
Bone Marrow Transplantation (2021)
-
Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT
Bone Marrow Transplantation (2020)
-
Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study
International Journal of Hematology (2011)